‡Contraindications include hypersensitivity to the active substance or to any of the excipients and clinically important active infections e.g. active tuberculosis.
Reproduced with permission.
*Not all patients are suitable for biologics. Please refer to the full BAD Guidelines and individual Summary of Product Characteristics when considering treatments. Reproduced from BAD Guidelines in which outcome evidence has been generated through a network meta-analysis which have limitations to be considered. Results are not from a single head to head study. Results are derived from the relative treatment rankings based on hierarchical clustering of the surface under the cumulative ranking curve estimates of efficacy (PGA 0/1 and/or PASI ≥90) and tolerability (withdrawal due to adverse events) at weeks 12-16. NMA performed using a bayesian approach to identify direct and indirect evidence comparing biologics at licensed doses with one another, MTX or placebo.
PBO - Placebo; MTX - methotrexate; ETA - etanercept; ADA - adalimumab; TIL - tildrakizumab; UST - ustekinumab; CZP - certolizumab pegol; INF - infliximab;
BRO - brodalumab; SEC - secukinumab; GUS - guselkumab; RIS - risankizumab; IXE - ixekizumab.
Dr Kave Shams discusses the mode of action of SKYRIZI and the IL-23/Th17 pathway
SKYRIZI mode of action animation
I want to find out more about SKYRIZI
I want to receive more information about SKYRIZI
- SKYRIZI: Summary of Product Characteristics.
- © NICE 2019 Risankizumab for treating moderate to severe psoriasis. Available from https://www.nice.org.uk/guidance All rights reserved. NICE is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
- Scottish Medicines Consortium. SMC2196. http://www.scottishmedicines.org.uk/medicines-advice.
- © NICE 2022 Risankizumab for treating active psoriatic arthritis. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
- Scottish Medicines Consortium. SMC2459. https://www.scottishmedicines.org.uk/medicines-advice.
- Papp K, et al. Long-Term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 4.5-Year Interim Analysis of the LIMMitless Open-Label Extension Trial. Presented at the 31st European Academy of Dermatology and Venereology Congress, (EADV 2022), 7–10 September 2022, Milan, Italy.
- Warren et al., Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
- Gordon KB et al. Lancet 2018;392: 650-661.
- Strober B, et al. Poster 1714, presented at the 28th European Academy of Dermatology and Venereology (EADV) Congress, 9 13 October 2019, Madrid, Spain.
- Reich K et al. Lancet 2019;394: 576-586.
- Kristensen LE et al. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results From the KEEPsAKE 1 and KEEPsAKE 2 Trials. Oral presentation EADV 30th Congress 2021 - Anniversary Edition 29 Sept – 2 Oct 2021.
- SKYRIZI Patient Information Leaflet - May 2021.
- Smith C.H et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020- a rapid update. 2020.
- Gooderham MJ et al. J Eur Acad Dermatol Venereol 2018; 32(7):1111-1119.
- Kofoed K et al. Acta Derm Venereol. 2015;95(2):133-139.
- Gaffen SL et al. Nat Rev Immunol 2014; 14(9): 585-600.
- Girolomoni G et al. J Eur Acad Dermatol Venereol 2017; 31(1): 1616-1626.
- Lynde CW et al. J Am Acad Dermatol 2014; 71(1): 141-150.
UK-RISN-220408. Date of preparation: January 2023.
SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
Some patients may not be suitable for SKYRIZI. You are advised to read the Prescribing Information (which can be found on tab above). Please also refer to the SKYRIZI Summary of Product Characteristics for important information including special warnings/precautions for use and summary of adverse reactions.
Study design information can be found on the Study Design page.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]